Fig. 3From: ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE studyData on exacerbations during benralizumab treatment. A Exacerbation occurrence. B Any exacerbation annual exacerbation rate (AER) variations C Severe exacerbation AER variations. Week 0 corresponds to the index dateBack to article page